New Treatments for Recurrent Uterine Cancer

• Published in: Current oncology reports Vol. 23; no. 12; p. 139
• Main Authors: Toboni, Michael D., Powell, Matthew A.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.12.2021; Springer Nature B.V
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemotherapy; Cytotoxicity; Endometrial cancer; Endometrium; ErbB-2 protein; Female; Gynecologic Cancers (J Brown and RW Naumann; Humans; Immunotherapy; Immunotherapy - methods; Medicine; Medicine & Public Health; Molecular Targeted Therapy - methods; Monoclonal antibodies; Oncology; Pembrolizumab; Phenylurea Compounds - therapeutic use; Quinolines - therapeutic use; Section Editors; Targeted cancer therapy; Topical Collection on Gynecologic Cancers; Trastuzumab; Trastuzumab - therapeutic use; Uterine cancer; Uterine Neoplasms - drug therapy; Targeted therapies; Recurrent endometrial cancer; Pembrolizumab; Uterine serous cancer; PD-L1; Lenvatinib; Trastuzumab
• ISSN: 1523-3790; 1534-6269
• DOI: 10.1007/s11912-021-01129-4

Purpose of Review Endometrial cancer is a highly treatable cancer; however, 13 to 15% of cases recur. Traditional cytotoxic chemotherapies have produced modest results, but new treatments show promise. This information was compiled from an extensive literature search, which was completed in order to summarize current data in this review. Our objective was to describe new therapies for recurrent endometrial cancer in the last 5 years. Recent Findings New targeted therapies are being identified for advanced and recurrent endometrial cancer. Within the last 5 years, pembrolizumab and lenvatinib have improved survival in advanced or recurrent endometrial cancer. Similarly, trastuzumab has shown efficacy in HER2-producing uterine serous cancer. Summary Patients with recurrent endometrial cancer are often difficult to salvage. Traditional chemotherapy has produced poor response rates. Both immunotherapy and other targeted therapies have shown promise in recurrent disease.